EGFR and non-small cell lung carcinoma: For example, tyrosine kinase inhibitors (TKIs) show significant clinical benefit in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-sensitizing mutations [4].